Progress in the management of limited-stage small cell lung cancer

Cancer

Volumn 120, Issue 6, 2014, Pages 790-798

  Amini, Arya ^a,b   Byers, Lauren A ^a   Welsh, James W ^a   Komaki, Ritsuko U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

accelerated radiotherapy; chemotherapy; hyperfractionated radiotherapy; lung cancer; radiotherapy; small cell

Indexed keywords

BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IMATINIB; PACLITAXEL; THALIDOMIDE; TOPOTECAN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG SMALL CELL CANCER; PARANEOPLASTIC SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ACCELERATED RADIOTHERAPY; CHEMOTHERAPY; HYPERFRACTIONATED RADIOTHERAPY; LUNG CANCER; RADIOTHERAPY; SMALL CELL;

DOSE FRACTIONATION; FOUR-DIMENSIONAL COMPUTED TOMOGRAPHY; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84896724080     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28505     Document Type: Review

References (80)

1. American Cancer Society. Global Cancer Facts & Figures. 2nd ed. Atlanta, GA: American Cancer Society; 2011.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
3. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
4. Cox JD, Ang KK, eds. Radiation Oncology: Rationale, Techniques, Results. 9th ed. Philadelphia, PA: Mosby; 2010.
5. Dowell JE,. Small cell lung cancer: are we making progress? Am J Med Sci. 2010; 339: 68-76.
6. Seute T, Leffers P, ten Velde GP, Twijnstra A,. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008; 112: 1827-1834. (Pubitemid 351536844)
7. Komaki R, Byhardt RW, Anderson T, et al. What is the lowest effective biologic dose for prophylactic cranial irradiation? Am J Clin Oncol. 1985; 8: 523-527. (Pubitemid 16206344)
8. Sorensen M, Pijls-Johannesma M, Felip E,. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v120-v125.
9. Simon GR, Turrisi A,. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132 (suppl 3): 324S-339S. (Pubitemid 47505212)
10. Foster NR, Mandrekar SJ, Schild SE, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2009; 115: 2721-2731.
11. Beasley MB, Brambilla E, Travis WD,. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40: 90-97. (Pubitemid 40417889)
12. Detterbeck FC, Boffa DJ, Tanoue LT,. The new lung cancer staging system. Chest. 2009; 136: 260-271.
13. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek E Jr,. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol. 2012; 4: 128-134.
14. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease? Lung Cancer. 2002; 37: 271-276. (Pubitemid 35286725)
15. Lee YJ, Cho A, Cho BC, et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res. 2009; 15: 2426-2432.
16. Poola I, Graziano SL,. Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res. 1998; 17: 165-173. (Pubitemid 28335575)
17. Prins J, De Vries EG, Mulder NH,. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. 1993; 13: 1373-1385. (Pubitemid 23334762)
18. van Meerbeeck JP, Fennell DA, De Ruysscher DK,. Small-cell lung cancer. Lancet. 2011; 378: 1741-1755.
19. Schild SE,. Thoracic Malignancies. 2nd ed. New York: Demos Medical Publishing; 2012.
20. Planchard D, Le Pechoux C,. Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer. 2011; 47 (suppl 3): S272-S283.
21. Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol. 2010; 5: 34-38.
22. Tai P, Yu E, Jones K, Sadikov E, Mahmood S, Tonita J,. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients with limited stage small cell lung cancer. Lung Cancer. 2006; 53: 211-215. (Pubitemid 43994241)
23. Hansen O, Sorensen P, Hansen KH,. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer. 2010; 68: 111-114.
24. Dearing MP, Steinberg SM, Phelps R, et al. Outcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years. J Clin Oncol. 1990; 8: 1042-1049. (Pubitemid 20200192)
25. Rawson NS, Peto J,. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990; 61: 597-604. (Pubitemid 20126342)
26. Hejazi RA, Zhang D, McCallum RW,. Gastroparesis, pseudoachalasia and impaired intestinal motility as paraneoplastic manifestations of small cell lung cancer. Am J Med Sci. 2009; 338: 69-71.
27. Lee HR, Lennon VA, Camilleri M, Prather CM,. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol. 2001; 96: 373-379.
28. Lucchinetti CF, Kimmel DW, Lennon VA,. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998; 50: 652-657.
29. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB,. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol. 1992; 141: 881-886.
30. Mussig K, Horger M, Haring HU, Wehrmann M,. Syndrome of inappropriate antidiuretic hormone secretion and ectopic ACTH production in small cell lung carcinoma. Lung Cancer. 2007; 57: 120-122. (Pubitemid 46843349)
31. Tantisattamo E, Ng RC,. Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature. Hawaii Med J. 2011; 70: 139-143.
32. Naveed S, Okoli K, Hollingsworth J, Kasmani R,. Guillain-Barre syndrome as a paraneoplastic manifestation of small-cell carcinoma of lung. South Med J. 2010; 103: 156-158.
33. Maddison P, Lang B,. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol. 2008; 201-202: 159-162.
34. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ,. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008; 26: 4276-4281.
35. Fox W, Scadding JG,. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet. 1973; 2: 63-65.
36. Miller AB, Fox W, Tall R,. Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet. 1969; 2: 501-505.
37. Hirsch FR, Hansen HH, Hansen M, et al. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol. 1987; 5: 585-591. (Pubitemid 17062496)
38. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20: 4665-4672. (Pubitemid 36025283)
39. Pignon JP, Arriagada R,. Role of thoracic radiotherapy in limited-stage small-cell lung cancer: quantitative review based on the literature versus meta-analysis based on individual data. J Clin Oncol. 1992; 10: 1819-1820. (Pubitemid 23059963)
40. Warde P, Payne D,. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992; 10: 890-895.
41. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002; 20: 3054-3060. (Pubitemid 34791094)
42. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993; 11: 336-344. (Pubitemid 23046826)
43. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006; 24: 1057-1063. (Pubitemid 46638802)
44. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22: 4837-4845.
45. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J, Kester A, Rutten I, Lambin P,. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev. 2007; 33: 461-473. (Pubitemid 47324226)
46. Bogart JA, Herndon JE 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004; 59: 460-468. (Pubitemid 38622601)
47. Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 1998; 16: 3528-3536. (Pubitemid 28506764)
48. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005; 62: 342-350. (Pubitemid 40704448)
49. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999; 340: 265-271. (Pubitemid 29063268)
50. Mauguen A, Le Pechoux C, Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012; 30: 2788-2797.
51. Komaki R, Paulus R, Ettinger DS, et al. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys. 2012; 83: e531-e536.
52. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995; 87: 183-190.
53. Arriagada R, Le Chevalier T, Riviere A, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol. 2002; 13: 748-754. (Pubitemid 34567382)
54. Rosen ST, Makuch RW, Lichter AS, et al. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response. Am J Med. 1983; 74: 615-624. (Pubitemid 13125979)
55. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999; 341: 476-484. (Pubitemid 29372887)
56. Le Pechoux C, Dunant A, Senan S, et al. Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009; 10: 467-474.
57. Le Pechoux C, Laplanche A, Faivre-Finn C, et al. Prophylactic Cranial Irradiation (PCI) Collaborative Group. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol. 2011; 22: 1154-1163.
58. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009; 27: 78-84.
59. Tai P, Assouline A, Joseph K, Stitt L, Yu E,. Prophylactic cranial irradiation for patients with limited-stage small-cell lung cancer with response to chemoradiation. Clin Lung Cancer. 2013; 14: 40-44.
60. Schild SE, Foster NR, Meyers JP, et al. North Central Cancer Treatment Group. Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol. 2012; 23: 2919-2924.
61. Shirvani SM, Juloori A, Allen PK, et al. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013; 87: 139-147.
62. Koay EJ, Lege D, Mohan R, Komaki R, Cox JD, Chang JY,. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012; 84: 1093-1100.
63. Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011; 117: 3004-3013.
64. Colaco RJ, Huh S, Nichols RC, et al. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer. Acta Oncol. 2013; 52: 506-513.
65. Xia B, Chen GY, Cai XW, et al. The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer. Radiat Oncol. 2011; 6: 50.
66. Komaki R, Moughan JD, Ettinger D, et al. Toxicities in a phase II study of accelerated high dose thoracic radiation therapy (TRT) with concurrent chemotherapy for limited small cell lung cancer (LSCLC) (RTOG 0239) [abstract]. J Clin Oncol 2007; 25 (18 suppl): 438s. Abstract 7717.
67. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 1016-1023. (Pubitemid 41505278)
68. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007; 18: 338-345. (Pubitemid 46323103)
69. Hu X, Bao Y, Zhang L, et al. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial. Cancer. 2012; 118: 278-287.
70. Arnold AM, Seymour L, Smylie M, et al. National Cancer Institute of Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007; 25: 4278-4284. (Pubitemid 47548568)
71. Lu C, Komaki R, Lee JS, et al. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003; 9: 2085-2091. (Pubitemid 36687629)
72. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2: 798-811.
73. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17: 658-667. (Pubitemid 29075255)
74. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005; 16: 1811-1816. (Pubitemid 41631245)
75. Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009; 27: 6006-6011.
76. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol. 2007; 25: 3945-3951. (Pubitemid 47477272)
77. Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012; 18: 3163-3169.
78. Chiappori AA, Schreeder MT, Moezi MM, et al. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer. 2012; 106: 839-845.
79. Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA. 2012; 109: 17034-17039.
80. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012; 44: 1111-1116.